In collaboration with the NCI, CDC, and BARDA, the FDA has developed a comprehensive dataset to compare the performance characteristics of different serological tests that were independently evaluated using well-characterized sample panels of positive and negative specimens for SARS-CoV-2 antibodies.
Source Link